GSK plc GSK

GSK PLC (LSE:GSK, NYSE:GSK) is expected to deliver a broadly in-line third quarter as weaker vaccine sales are offset by strength in HIV treatments and respiratory drug Nucala, according to RBC Capital Markets. The broker reiterated its Sector Perform rating and 1,975p price target ahead of...

GSK (LSE:GSK) announced a new collaboration with Chai Discovery to apply AI-driven protein design in its drug discovery pipeline. The partnership gives GSK access to Chai Discovery's protein folding and design models that are focused on early stage R&D. Internal GSK evaluations reported hits against all tested targets when using Chai Discovery's AI tools in preclinical research. The Chai Discovery AI protein design collaboration is important, but investors should weigh it alongside GSK's...

GSK plc (LSE/NYSE: GSK) today announced a partnership with award-winning actress, producer and philanthropist Viola Davis to launch "Shingles, actually", a new educational campaign designed to spark conversations about the realities of aging, including the risk of shingles for adults 50 years and older. As part of the "Shingles, actually" campaign, Viola discusses her own experience with shingles for the first time, including its impact on her work and personal life, while encouraging the 50+ co

GSK (LSE:GSK) has entered a collaboration with Wave Life Sciences to advance a GalNAc-siRNA hepatology candidate into its development pipeline. The partnership with Wave Life Sciences focuses on RNA-based therapies targeting liver diseases using GalNAc-siRNA technology. GSK expanded its tuberculosis research with AN2 Therapeutics, supported by new funding from the Bill & Melinda Gates Foundation for boron-based drug discovery. The Wave Life Sciences hepatology move and fresh Gates-backed TB...

GSK has pulled off a 52.5% share price gain over the past 5 years, yet with recent weakness on the screen, the live question for investors is whether that track record lines up with what the company is actually earning today. The issue is not just where the stock has come from, but whether GSK's current earnings power still supports the price you see now. That 52.5% rise over 5 years puts real weight on the question of whether GSK's current earnings profile can carry the valuation further or...

LONDON, October 06, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced the phase IIIb CROWN study met its primary endpoint, demonstrating that at six months, long-acting Cabenuva (cabotegravir + rilpivirine [CAB + RPV LA]) achieved superior rates of viral suppression compared with standard-of-care oral antiretroviral therapy (ART) in adults and adolescents living with HIV-1 who had detectable virus when they entered the

Cerebras stock cratered to a post-IPO low while rivals like NVIDIA and AMD surged, yet one of the world's largest banks just doubled down with a price target that implies the market is deeply, fundamentally wrong about this AI chip maker.

Markets are back to obsessing over central bank signals, supply routes and growth downgrades, and that mix is shaking up how investors look at reliable income. When credit feels tighter and headlines keep flagging disruption risks, steady dividend cheques from global healthcare stocks can suddenly look more interesting. This piece walks through three healthcare dividend payers from our screener that appear closely exposed to the latest macro news and explains why their stories might matter to...

Fresh funding from the Gates Foundation for AN2 Therapeutics’ tuberculosis collaboration with GSK (LSE:GSK) has put the pharma group’s boron based LeuRS inhibitor program back in focus for investors. The GSK share price has softened in the very short term, with a 1-day share price return of a 0.22% decline and a 7-day share price return of a 2.62% decline, even as fresh R&D headlines such as the Gates backed TB work and recent conference appearances keep the pipeline in view. Yet momentum...

– Hatteras holds first closing of Hatteras Opportunity Fund II (HOF II) – – HOF II closing brings capital under management to over $1 billion – DURHAM, N.C., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Hatteras Venture Partners, a venture capital firm focused on transformative healthcare innovation, has appointed two longtime healthcare leaders to senior roles as it builds its next generation of companies and expands support for later-stage portfolio businesses. Sir Andrew Witty, former Chief Executive O

Investment bank Jefferies has kept its ‘buy’ rating and 2,500p target on GSK PLC (LSE:GSK, NYSE:GSK), the FTSE 100 drugmaker, after a fireside chat with its chief scientific officer reinforced its view that B7H3 is one of GSK's most underappreciated opportunities. The target implies 35%...

GSK plc (NYSE:GSK) has spent much of 2026 adding new drugs to its pipeline, and Berenberg is starting to think investors aren’t giving it enough credit. Berenberg analyst Kerry Holford upgraded GSK from Hold to Buy and raised the firm’s price target to 2,200p from 2,000p on September 15. Berenberg said it is “increasingly optimistic” […]

GSK plc (NYSE:GSK) is adding another cancer drug to a pipeline that has been getting considerably more attention under CEO Luke Miels. The company has agreed to acquire full global rights to a trispecific T-cell engager from China-based Chimagen Biosciences in a deal worth up to $750 million. GSK (NYSE:GSK) plans to develop the experimental […]